The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance

Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.

(2016) Solen Pichereau et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

(2014) Katsuhiko Higuchi et al.   EUROPEAN JOURNAL OF CANCER

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer

(2014) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509

(2014) Miyako Satouchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

(2013) B. Schultheis et al.   ANNALS OF ONCOLOGY

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

(2013) Thomas Morel et al.   Orphanet Journal of Rare Diseases

Personalized medicine in oncology: where have we come from and where are we going?

(2013) Fabrice André et al.   PHARMACOGENOMICS

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians

(2013) X Liu et al.   PHARMACOGENOMICS JOURNAL

Early evaluation and value-based pricing of regenerative medicine technologies

(2013) Florian Koerber et al.   Regenerative Medicine

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis

(2012) Mafalda M Dias et al.   PHARMACOGENOMICS

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

(2011) E Marcuello et al.   BRITISH JOURNAL OF CANCER

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

(2011) L Bennett et al.   BRITISH JOURNAL OF CANCER

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients

(2011) Katerina Shulman et al.   CANCER

Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting

(2011) Christian Asseburg et al.   CLINICAL THERAPEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

(2010) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

(2010) E Martinez-Balibrea et al.   BRITISH JOURNAL OF CANCER

Risk of mortality in patients with cancer who experience febrile neutropenia

(2010) Gary H. Lyman et al.   CANCER

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

(2010) J. Randolph Hecht et al.   Clinical Colorectal Cancer

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies

(2010) François Ghiringhelli et al.   INVESTIGATIONAL NEW DRUGS

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer

(2009) Heather Taffet Gold et al.   CANCER

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

(2009)   GENETICS IN MEDICINE

The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study

(2009) Wolf H. Rogowski   MEDICAL DECISION MAKING

Challenges of translating genetic tests into clinical and public health practice

(2009) Wolf H. Rogowski et al.   NATURE REVIEWS GENETICS

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

(2009) Christoph Schulz et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

(2008) E. Aranda et al.   ANNALS OF ONCOLOGY

Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer

(2008) Marko Obradovic et al.   PHARMACOGENOMICS

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research